Nov 29, 2022 8:50am EST Lexaria’s DehydraTECH-CBD(TM) Enhances Performance Compared to Epidiolex(R) in Seizure Study Program
Nov 01, 2022 9:25am EDT Lexaria Receives Independent Review Board Approval for its Upcoming Human Oral Nicotine Study
Aug 11, 2022 8:30am EDT Lexaria Bioscience Corp. (NASDAQ: LEXX) Focused on Filling Need for Hypertension Treatment Solution
Aug 10, 2022 8:15am EDT Lexaria Announces Positive Feedback from Pre-IND Meeting with FDA on DehydraTECH-CBD for Hypertension
